Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Monnery, L.
Right arrow Articles by Charlton, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monnery, L.
Right arrow Articles by Charlton, G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 2001, Vol. 87, No. 2 295-298
© 2001 The Board of Management and Trustees of the British Journal of Anaesthesia


Case Reports

Primary pulmonary hypertension in pregnancy; a role for novel vasodilators

L. Monnery1, J. Nanson2 and G. Charlton3

1Department of Anaesthesia, Dorset County Hospital, Williams Avenue, Dorchester DT1 2JY, UK. 2Department of Anaesthesia, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK. 3Shackleton Department of Anaesthetics, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK*Corresponding author

We describe the case of a 28-week pregnant woman presenting with severe primary pulmonary hypertension (PPH). She had an elective Caesarean section under general anaesthesia at 32 weeks gestation. Pulmonary artery pressures (PAP) measured from a pulmonary artery catheter before anaesthesia were in excess of 100 mm Hg. Intraoperative nitric oxide was used to reduce PAP. After the delivery of a healthy infant PAP was controlled with nebulized iloprost and a prostacyclin infusion. Seven days later she was discharged from intensive care taking an oral calcium antagonist and warfarin. She developed intractable right heart failure and died 14 days after delivery. Despite increasing experience in the use of drugs to reduce PAP, the clinical course of pregnancy complicated by severe PPH is usually fatal.

Br J Anaesth 2001; 87: 295–8


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart JHome page
E. Bedard, K. Dimopoulos, and M. A. Gatzoulis
Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?
Eur. Heart J., February 1, 2009; 30(3): 256 - 265.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
S. Huang and E. R. H. DeSantis
Treatment of pulmonary arterial hypertension in pregnancy
Am. J. Health Syst. Pharm., September 15, 2007; 64(18): 1922 - 1926.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. A. Elliot, P. Stewart, V. J. Webster, G. H. Mills, S. P. Hutchinson, E. S. Howarth, F. A. Bu'Lock, R. A. Lawson, I. J. Armstrong, and D. G. Kiely
The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension
Eur. Respir. J., July 1, 2005; 26(1): 168 - 173.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
P. Ray, G. J. Murphy, and L. E. Shutt
Recognition and management of maternal cardiac disease in pregnancy
Br. J. Anaesth., September 1, 2004; 93(3): 428 - 439.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
W.-R. Chou, P.-H. Kuo, J.-C. Shih, and P.-C. Yang
A 31-Year-Old Pregnant Woman With Progressive Exertional Dyspnea and Differential Cyanosis
Chest, August 1, 2004; 126(2): 638 - 641.
[Full Text] [PDF]


Home page
ChestHome page
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 35S - 62S.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.